KEY POINTS
- This Breaking News Editorial in Neuro-Oncology discusses the recently published INTRAGO-II randomized phase III trial, described by the authors as the largest randomized evaluation of focal radiation dose escalation in newly diagnosed glioblastoma. The editorial argues that the negative results have implications beyond the specific intraoperative radiotherapy technique tested.
- INTRAGO-II evaluated the addition of 30 Gy intraoperative radiotherapy to the resection cavity during glioblastoma treatment. According to the editorial, this additional focal dose did not improve progression-free survival, overall survival or local tumor control. These findings are drawn from the separately published randomized trial; the present article provides an expert interpretation rather than an independent trial analysis.
- The editorial emphasizes that approximately 70% of recurrences in both treatment arms occurred within 1 cm of the resection cavity, despite substantial radiation dose escalation at the surgical site. The persistence of predominantly local relapse suggests that insufficient physical dose may not be the principal explanation for treatment failure in many glioblastomas.
- A particularly important observation concerns patients with measurable residual tumor. Even where residual disease was located within the intended high-dose region, the authors report no detectable benefit from additional irradiation, challenging the assumption that increasing local dose necessarily produces greater tumor-cell eradication.
- The authors place INTRAGO-II within a longer history of unsuccessful glioblastoma dose-escalation strategies, including intensified external-beam RT, brachytherapy and highly focal techniques. They argue that the accumulated evidence favors reassessing the biological premise of repeated physical dose escalation rather than pursuing increasingly complex methods of delivering higher doses to the same anatomical regions.
- Potential biological explanations include intrinsic radioresistance, interconnected tumor-cell networks formed through tumor microtubes, and radiation-induced changes in the pericavitary microenvironment. The editorial highlights possible contributions from hypoxia, cellular senescence, inflammation, vascular changes and depletion of local immune-competent cells, although these mechanisms were not directly tested in the INTRAGO-II clinical trial.
- The proposed direction for future research is to combine RT with biologically targeted strategies, particularly approaches that disrupt tumor-cell networks or modify treatment-induced microenvironmental resistance. The authors argue that glioblastoma research should prioritize these combinations over further focal dose escalation, but the editorial does not establish that any specific network-disrupting intervention improves patient outcomes.
CLINICAL TAKEAWAY
The negative INTRAGO-II findings strengthen the argument against routine focal radiation dose escalation for newly diagnosed glioblastoma outside appropriately designed trials. This editorial makes a compelling case for investigating tumor-cell networks and microenvironment-mediated radioresistance, although its proposed biological strategies remain investigational and require prospective clinical validation.